Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

(A) Flow cytometry analysis of specific Mo markers CD11b and CD14 expression was performed from day 0 to 5 (d5) in U937 cells treated with vitamin D3 (VITD3) to induce Mo differentiation, as compared to untreated U937 control cells (d0). (B) Real time PCR analysis of TM9SF4 mRNA expression during VITD3: induced Mo differentiation of U937 cells. (C, D) Western blot (C) and flow cytometry analysis (D) of TM9SF4 protein expression in VITD3-treated U937 cells, as compared to untreated control U937 cells (d0). (E) Flow cytometry analysis of G markers CD11b and CD54 was performed from day 0 to 5 (d5) in HL-60 treated with all trans retinoic acid (ATRA) for G differentiation, as compared to untreated HL-60 control cells (d0). (F) Real time PCR analysis of TM9SF4 mRNA expression during ATRA: induced G differentiation of HL-60 cells. (G, H) Western blot (G) and flow cytometry analysis (H) of TM9SF4 protein expression in ATRA-treated HL-60 cells, as compared to untreated control HL-60 cells (d0). (A, B, D, E, F, H) The results of three independent experiments (mean ±SEM values) are shown; *, **, *** are p<0.05, p<0.01, p<0.001 respectively; n.s. is for not significant. (A, D, E, H) MFI is for Mean Fluorescence intensity. (B, F) A.U. is for arbitrary units. (C, G) One representative experiment out of three is shown; actin is shown as an internal control; (C) 293T is for 293T(pcDNA3.1/TM9SF4) overexpressing cells used as a positive control of TM9SF4 protein expression.

Source: TM9SF4 is expressed in CD34+ HPCs and during monocytic (Mo) and granulocytic (G) differentiation of HPCs, but is overexpressed in AMLs. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Laboratory / cell research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Human primary leukemic blasts obtained from AML patients, were maintained in culture in vitro in Iscove’s medium supplemented with 10% FCS, GM-CSF (10 ng/ml), SCF (50 ng/ml), IL-3 (10 ng/ml) (PeproTech Inc.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Human TM9SF4 Is a New Gene Down-Regulated by Hypoxia and Involved in Cell Adhesion of Leukemic Cells

Study design awaiting verification · PLoS ONE · 2015

Original publication title

Human TM9SF4 Is a New Gene Down-Regulated by Hypoxia and Involved in Cell Adhesion of Leukemic Cells

Rosa Paolillo; Isabella Spinello; Maria Teresa Quaranta; Luca Pasquini; Elvira Pelosi; Francesco Lo Coco; Ugo Testa; Catherine Labbaye

© 2015 Paolillo et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Altogether, our study reports for the first time the expression of TM9SF4 at the level of normal and leukemic hematopoietic cells and its marked expression at the level of AMLs displaying granulocytic differentiation.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

The transmembrane 9 superfamily protein member 4, TM9SF4, belongs to the TM9SF family of proteins highly conserved through evolution. TM9SF4 homologs, previously identified in many different species, were mainly involved in cellular adhesion, innate immunity and phagocytosis. In human, the function and biological significance of TM9SF4 are currently under investigation. However, TM9SF4 was found overexpressed in human metastatic melanoma and in a small subset of acute myeloid leukemia (AMLs) and myelodysplastic syndromes, consistent with an oncogenic function of this gene.

Source: Background

Abstract: Purpose and Results

In this study, we first analyzed the expression and regulation of TM9SF4 in normal and leukemic cells and identified TM9SF4 as a gene highly expressed in human quiescent CD34+ hematopoietic progenitor cells (HPCs), regulated during monocytic and granulocytic differentiation of HPCs, both lineages giving rise to mature myeloid cells involved in adhesion, phagocytosis and immunity. Then, we found that TM9SF4 is markedly overexpressed in leukemic cells and in AMLs, particularly in M2, M3 and M4 AMLs (i.e., in AMLs characterized by the presence of a more or less differentiated granulocytic progeny), as compared to normal CD34+ HPCs.

Proliferation and differentiation of HPCs occurs in hypoxia, a physiological condition in bone marrow, but also a crucial component of cancer microenvironment. Here, we investigated the impact of hypoxia on TM9SF4 expression in leukemic cells and identified TM9SF4 as a direct target of HIF-1α, downregulated in these cells by hypoxia. Then, we found that the hypoxia-mediated downregulation of TM9SF4 expression is associated with a decrease of cell adhesion of leukemic cells to fibronectin, thus demonstrating that human TM9SF4 is a new molecule involved in leukemic cell adhesion.

Source: Purpose and Results

Abstract: Conclusions

Altogether, our study reports for the first time the expression of TM9SF4 at the level of normal and leukemic hematopoietic cells and its marked expression at the level of AMLs displaying granulocytic differentiation.

Source: Conclusions
Authors’ abstract

Background

The transmembrane 9 superfamily protein member 4, TM9SF4, belongs to the TM9SF family of proteins highly conserved through evolution. TM9SF4 homologs, previously identified in many different species, were mainly involved in cellular adhesion, innate immunity and phagocytosis. In human, the function and biological significance of TM9SF4 are currently under investigation. However, TM9SF4 was found overexpressed in human metastatic melanoma and in a small subset of acute myeloid leukemia (AMLs) and myelodysplastic syndromes, consistent with an oncogenic function of this gene.

Purpose and Results

In this study, we first analyzed the expression and regulation of TM9SF4 in normal and leukemic cells and identified TM9SF4 as a gene highly expressed in human quiescent CD34+ hematopoietic progenitor cells (HPCs), regulated during monocytic and granulocytic differentiation of HPCs, both lineages giving rise to mature myeloid cells involved in adhesion, phagocytosis and immunity. Then, we found that TM9SF4 is markedly overexpressed in leukemic cells and in AMLs, particularly in M2, M3 and M4 AMLs (i.e., in AMLs characterized by the presence of a more or less differentiated granulocytic progeny), as compared to normal CD34+ HPCs.

Proliferation and differentiation of HPCs occurs in hypoxia, a physiological condition in bone marrow, but also a crucial component of cancer microenvironment. Here, we investigated the impact of hypoxia on TM9SF4 expression in leukemic cells and identified TM9SF4 as a direct target of HIF-1α, downregulated in these cells by hypoxia. Then, we found that the hypoxia-mediated downregulation of TM9SF4 expression is associated with a decrease of cell adhesion of leukemic cells to fibronectin, thus demonstrating that human TM9SF4 is a new molecule involved in leukemic cell adhesion.

Conclusions

Altogether, our study reports for the first time the expression of TM9SF4 at the level of normal and leukemic hematopoietic cells and its marked expression at the level of AMLs displaying granulocytic differentiation.

Publication and source details

Original title: Human TM9SF4 Is a New Gene Down-Regulated by Hypoxia and Involved in Cell Adhesion of Leukemic Cells

Rosa Paolillo; Isabella Spinello; Maria Teresa Quaranta; Luca Pasquini; Elvira Pelosi; Francesco Lo Coco; Ugo Testa; Catherine Labbaye

PLoS ONE · 2015

Competing Interests: The authors have declared that no competing interests exist.

Conceived and designed the experiments: RP CL. Performed the experiments: RP IS MTQ LP. Analyzed the data: RP IS MTQ UT CL. Contributed reagents/materials/analysis tools: EP FLC. Wrote the paper: RP UT CL. Gained funding: CL.

* E-mail: catherine.labbaye@iss.it
© 2015 Paolillo et al2015Paolillo et alhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.This study was supported by institutional grant from the Italian Ministry of Health to C.L (RF-2010-2312222). R.P was supported by fellowship from the Lady Tata Memorial Trust Foundation (2012-2013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T20:30:10.424142+00:00

DOI: 10.1371/journal.pone.0126968 · PMC4427288